As of Oct 20
| -0.72 / -5.03%|
The 7 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 18.50, with a high estimate of 20.00 and a low estimate of 15.00. The median estimate represents a +36.13% increase from the last price of 13.59.
The current consensus among 7 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.